Ligand Pharmaceuticals Inc.

473 articles with Ligand Pharmaceuticals Inc.

• Ligand CEO Issues Letter to Captisol Customers

  6/1/2020

  Ligand Pharmaceuticals Incorporated announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers.

• Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

  5/29/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new pro

• Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics

  5/28/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors.

• Ligand Reports First Quarter 2020 Financial Results

  5/6/2020

  Ligand Pharmaceuticals Incorporated reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates.

• Ligand’s First Quarter Financial Results to be Reported May 6th

  4/22/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report first quarter 2020 financial results on May 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. What: Ligand conference call to discuss financial results and provide general business updates  

• Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call

  4/6/2020

  Ligand Provides a Corporate Update and Announces May 6 th as the Date for First Quarter Earnings

• Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies

  4/2/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations

• Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com

  3/10/2020

  Ligand Pharmaceuticals Incorporated announces that scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured.

• Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March

  3/2/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at two upcoming investor conferences.

• Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales

  2/27/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance.

• Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen

  2/11/2020

  Ligand Pharmaceuticals Incorporated announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules for $15 million in cash.

• Ligand Reports Fourth Quarter and Full Year 2019 Financial Results

  2/6/2020

  Conference Call and Webcast with Slides Begins at 4:30 p.m. Eastern Time Today

• Ligand's Technologies Support and Enable Potential Coronavirus Treatments

  2/3/2020

  Partner Gilead Sciences’ Captisol®-enabled remdesivir (GS-5734) highlighted in the New England Journal of Medicine for treating the first case of the 2019 novel coronavirus in the United States

• Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

  1/13/2020

  OmniAb technology to be accessed by Pandion for range of discovery programs

• Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th

  1/9/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020.

• Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine

  12/23/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that two members of its Board of Directors, Nancy Gray and Sarah Boyce, have been named to WomenInc. magazine’s 2019 Most Influential Corporate Directors list.

• Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi

  12/2/2019

  Sanofi will pay Ligand an up-front platform access fee, development and regulatory milestone payments and potential royalties on sales of marketed products.

• Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™

  11/12/2019

  Ligand’s revenue grew 250% during the period upon which this list is based.

• Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

  11/8/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN Kidney Week 2019 in Washington, D.C.

• Ligand to Participate in the Stephens 2019 Nashville Investment Conference

  11/7/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat is scheduled to take place on Wednesday, November 13, 2019 at 3:30 p.m. Eastern Time.